Interestingly, unlike normal B cells in which BAFF-mediated survival depends on the activation of the alternate NF-κB2 pathway via BAFF-R (16), CLL cells rely on the activation of the classical NF-κB1 pathway via TACI and BCMA, as blocking BAFF-R alone did not affect CLL cell survival in vitro (22). The gene discussed is NFKB2; the disease is B-cell chronic lymphocytic leukemia.